Our Mission is to make world vaccination possible
Recent scientific publications show that vaccines delivered to the lungs are more effective than traditional injectable vaccines and provide broader cross-reactive and longer-lasting protection.
Revax patented low-dose technology enables the world to be better prepared. To react more quickly for newly emerging respiratory pathogens and for mutations or variants of existing threats, thereby contributing to the G7 100 day mission, detailed here.
By bringing together key players in aerosol delivery, academic excellence in vaccines, industrial support and clinical research organisation expertise, Revax Biotech promises to deliver a revolution in vaccination. This will enable rapid development of safer vaccines at dose levels which will be economic for global distribution due to the low volume of material and no cold chain requirement and therefore provide for the Inclusion of LMIC and developing countries.